Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 28 of 95, showing 5 Applications out of 471 total, starting on record 136, ending on 140

# Protocol No Study Title Investigator(s) & Site(s)

136.

ECCT/22/02/02   The Women TAF-FTC Benchmark
    Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women   
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
View

137.

ECCT/22/02/01   An Open label Inclacumab study
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View

138.

ECCT/22/01/06   AIKILI Technology
    Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology       
Principal Investigator(s)
1. Laura Kelley Kelley
Site(s) in Kenya
Aga Khan University Hospital, Nairobi.
 
View

139.

ECCT/22/01/05   STEP-Mag Trial
    Simplified Treatment for Eclampsia Prevention using Magnesium sulfate:  A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Nakuru Level V Hospital (Nakuru county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
3. Naivasha Level IV Hospital (Nakuru county)
 
View

140.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View